Animal model results gooses Dicerna price


Demonstrating the upside benefits of being a thinly-traded stock, Dicerna Pharmaceuticals (DRNA +21.5%) jumps on turnover of 353K shares, a 2x surge in volume. The upside move is being driven by the news that DCR-PH1, its therapeutic candidate for primary hyperoxaluria type 1 (PH1), inhibits the gene implicated in the pathogenesis of the disease. Investors' enthusiasm might be a bit premature considering that the encouraging results were observed in a preclinical animal model.

In genetically-modified PH1 mice, researchers noted a 97% reduction in in the HAO1 transcript in the liver after a single dose of DCR-PH1 and a significant reduction in urinary oxalate levels, a key marker of the disease. Urinary oxalate levels returned to near baseline in DCR-PH1-treated mice.

PH1 is a rare inherited liver disorder that often results in progressive and severe kidney damage.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs